These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9652687)

  • 21. Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use.
    Wolfort FG; Cetrulo CL; Nevarre DR
    Plast Reconstr Surg; 1999 Nov; 104(6):1814-20; discussion 1821-2. PubMed ID: 10541186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.
    Holstein A; Plaschke A; Egberts EH
    Exp Clin Endocrinol Diabetes; 2001; 109(8):389-92. PubMed ID: 11748485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of 14 cases.
    Pujol RM; Domingo P; Xavier-Matias-Guiu ; Francia E; Sanbeat MA; Alomar A; Vazquez G
    J Am Acad Dermatol; 2000 Feb; 42(2 Pt 1):193-8. PubMed ID: 10642672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in body shape and metabolic abnormalities.
    Res Initiat Treat Action; 1999 Jan; 5(1):18. PubMed ID: 11366225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyen TH; Chevenne D; Capeau J; Rozenbaum W
    Diabetes Metab; 1999 Sep; 25(3):225-32. PubMed ID: 10499191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid evaluation in HIV-1-positive patients treated with protease inhibitors.
    Schmidt HH; Behrens G; Genschel J; Stoll M; Dejam A; Haas R; Manns MP; Schmidt RE
    Antivir Ther; 1999; 4(3):163-70. PubMed ID: 12731756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV protease inhibitors and obesity.
    Anuurad E; Bremer A; Berglund L
    Curr Opin Endocrinol Diabetes Obes; 2010 Oct; 17(5):478-85. PubMed ID: 20717021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
    Brinkman K; Smeitink JA; Romijn JA; Reiss P
    Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.
    Martinez E; Mocroft A; García-Viejo MA; Pérez-Cuevas JB; Blanco JL; Mallolas J; Bianchi L; Conget I; Blanch J; Phillips A; Gatell JM
    Lancet; 2001 Feb; 357(9256):592-8. PubMed ID: 11558485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiretroviral protease inhibitor therapy leads to hyperglycaemia, hyperlipidaemia and lipodystrophy.
    Sangraula H; Sharma KK; Dwivedi S
    Natl Med J India; 2001; 14(6):347-8. PubMed ID: 11804366
    [No Abstract]   [Full Text] [Related]  

  • 31. Metabolic complications of protease inhibitors: what have we learned so far?
    Erbelding EJ
    Hopkins HIV Rep; 1999 Mar; 11(2):5, 15. PubMed ID: 11366249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.
    Temple ME; Koranyi KI; Nahata MC
    Ann Pharmacother; 2003 Sep; 37(9):1214-8. PubMed ID: 12921501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ectopic lipid accumulation: A potential cause for metabolic disturbances and a contributor to the alteration of kidney function.
    Guebre-Egziabher F; Alix PM; Koppe L; Pelletier CC; Kalbacher E; Fouque D; Soulage CO
    Biochimie; 2013 Nov; 95(11):1971-9. PubMed ID: 23896376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of sex and race on lipodystrophy pathogenesis.
    Nolan D; Mallal S
    J HIV Ther; 2001 May; 6(2):32-6. PubMed ID: 11501201
    [No Abstract]   [Full Text] [Related]  

  • 35. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management.
    Carr A
    AIDS; 2003 Apr; 17 Suppl 1():S141-8. PubMed ID: 12870540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fat, sugar and drugs on the French Riviera.
    Lands L
    GMHC Treat Issues; 1999 Mar; 13(3):9-11. PubMed ID: 11366205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lipids and AIDS].
    Ducobu J; Payen MC
    Rev Med Brux; 2000 Feb; 21(1):11-7. PubMed ID: 10748683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The lipodystrophy syndrome and protease inhibitor therapy in HIV infection].
    Djokic M; Bojic I; Mikic D; Begovic V; Kuljic-Kapulica N; Karadaglic Dj; Dimitrijevic-Rajic R; Curcic P; Hristovic D
    Vojnosanit Pregl; 2001; 58(4):433-5. PubMed ID: 11712226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.
    Gupta S; Knight AG; Losso BY; Ingram DK; Keller JN; Bruce-Keller AJ
    Antiviral Res; 2012 Jul; 95(1):19-29. PubMed ID: 22580130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy?
    Goulbourne CN; Vaux DJ
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):292-6. PubMed ID: 20074077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.